IRIDEX Competitors

IRIDEX (NASDAQ:IRIX) and Edap Tms (NASDAQ:EDAP) are both small-cap computer and technology companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, valuation and risk.

Volatility & Risk

IRIDEX has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Comparatively, Edap Tms has a beta of 1.92, meaning that its stock price is 92% more volatile than the S&P 500.

Profitability

This table compares IRIDEX and Edap Tms' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and price targets for IRIDEX and Edap Tms, as reported by MarketBeat.

IRIDEX presently has a consensus target price of $6.50, indicating a potential downside of 15.69%. Edap Tms has a consensus target price of $12.50, indicating a potential upside of 37.67%. Given Edap Tms' higher probable upside, analysts clearly believe Edap Tms is more favorable than IRIDEX.

Earnings and Valuation

This table compares IRIDEX and Edap Tms' revenue, earnings per share (EPS) and valuation.

Edap Tms has higher revenue and earnings than IRIDEX. IRIDEX is trading at a lower price-to-earnings ratio than Edap Tms, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

32.6% of IRIDEX shares are owned by institutional investors. 2.0% of IRIDEX shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Edap Tms beats IRIDEX on 10 of the 13 factors compared between the two stocks.

Second Sight Medical Products (NASDAQ:EYES) and IRIDEX (NASDAQ:IRIX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, dividends and risk.

Volatility and Risk

Second Sight Medical Products has a beta of 2.49, suggesting that its stock price is 149% more volatile than the S&P 500. Comparatively, IRIDEX has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500.

Earnings & Valuation

This table compares Second Sight Medical Products and IRIDEX's top-line revenue, earnings per share and valuation.

IRIDEX has higher revenue and earnings than Second Sight Medical Products. IRIDEX is trading at a lower price-to-earnings ratio than Second Sight Medical Products, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Second Sight Medical Products and IRIDEX's net margins, return on equity and return on assets.

Institutional & Insider Ownership

4.1% of Second Sight Medical Products shares are owned by institutional investors. Comparatively, 32.6% of IRIDEX shares are owned by institutional investors. 67.5% of Second Sight Medical Products shares are owned by company insiders. Comparatively, 2.0% of IRIDEX shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Second Sight Medical Products and IRIDEX, as provided by MarketBeat.

IRIDEX has a consensus price target of $6.50, indicating a potential downside of 15.69%. Given IRIDEX's higher probable upside, analysts clearly believe IRIDEX is more favorable than Second Sight Medical Products.

Summary

IRIDEX beats Second Sight Medical Products on 8 of the 13 factors compared between the two stocks.

IRIDEX (NASDAQ:IRIX) and BioSig Technologies (NASDAQ:BSGM) are both small-cap computer and technology companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

Risk & Volatility

IRIDEX has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Comparatively, BioSig Technologies has a beta of 1.83, meaning that its stock price is 83% more volatile than the S&P 500.

Earnings and Valuation

This table compares IRIDEX and BioSig Technologies' gross revenue, earnings per share (EPS) and valuation.

IRIDEX has higher revenue and earnings than BioSig Technologies.

Profitability

This table compares IRIDEX and BioSig Technologies' net margins, return on equity and return on assets.

Institutional & Insider Ownership

32.6% of IRIDEX shares are held by institutional investors. Comparatively, 18.3% of BioSig Technologies shares are held by institutional investors. 2.0% of IRIDEX shares are held by company insiders. Comparatively, 19.5% of BioSig Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for IRIDEX and BioSig Technologies, as reported by MarketBeat.com.

IRIDEX presently has a consensus target price of $6.50, indicating a potential downside of 15.69%. Given IRIDEX's higher possible upside, equities analysts clearly believe IRIDEX is more favorable than BioSig Technologies.

Summary

IRIDEX beats BioSig Technologies on 7 of the 10 factors compared between the two stocks.

IRIDEX (NASDAQ:IRIX) and FONAR (NASDAQ:FONR) are both small-cap computer and technology companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

Risk & Volatility

IRIDEX has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Comparatively, FONAR has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for IRIDEX and FONAR, as reported by MarketBeat.com.

IRIDEX presently has a consensus target price of $6.50, indicating a potential downside of 15.69%. Given IRIDEX's higher possible upside, equities analysts clearly believe IRIDEX is more favorable than FONAR.

Earnings and Valuation

This table compares IRIDEX and FONAR's gross revenue, earnings per share (EPS) and valuation.

FONAR has higher revenue and earnings than IRIDEX.

Profitability

This table compares IRIDEX and FONAR's net margins, return on equity and return on assets.

Institutional & Insider Ownership

32.6% of IRIDEX shares are held by institutional investors. Comparatively, 62.1% of FONAR shares are held by institutional investors. 2.0% of IRIDEX shares are held by company insiders. Comparatively, 8.6% of FONAR shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

FONAR beats IRIDEX on 8 of the 12 factors compared between the two stocks.

Soleno Therapeutics (NASDAQ:SLNO) and IRIDEX (NASDAQ:IRIX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

Valuation and Earnings

This table compares Soleno Therapeutics and IRIDEX's gross revenue, earnings per share and valuation.

IRIDEX has higher revenue and earnings than Soleno Therapeutics. IRIDEX is trading at a lower price-to-earnings ratio than Soleno Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Soleno Therapeutics has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500. Comparatively, IRIDEX has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Soleno Therapeutics and IRIDEX, as reported by MarketBeat.com.

Soleno Therapeutics presently has a consensus target price of $8.6667, indicating a potential upside of 653.62%. IRIDEX has a consensus target price of $6.50, indicating a potential downside of 15.69%. Given Soleno Therapeutics' higher possible upside, equities research analysts plainly believe Soleno Therapeutics is more favorable than IRIDEX.

Institutional and Insider Ownership

55.4% of Soleno Therapeutics shares are owned by institutional investors. Comparatively, 32.6% of IRIDEX shares are owned by institutional investors. 74.9% of Soleno Therapeutics shares are owned by company insiders. Comparatively, 2.0% of IRIDEX shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Soleno Therapeutics and IRIDEX's net margins, return on equity and return on assets.

IRIDEX (NASDAQ:IRIX) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap computer and technology companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, valuation, profitability, dividends and institutional ownership.

Valuation and Earnings

This table compares IRIDEX and ENDRA Life Sciences' revenue, earnings per share (EPS) and valuation.

IRIDEX has higher revenue and earnings than ENDRA Life Sciences. IRIDEX is trading at a lower price-to-earnings ratio than ENDRA Life Sciences, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

IRIDEX has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, ENDRA Life Sciences has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for IRIDEX and ENDRA Life Sciences, as provided by MarketBeat.com.

IRIDEX currently has a consensus price target of $6.50, suggesting a potential downside of 15.69%. Given IRIDEX's higher possible upside, equities research analysts clearly believe IRIDEX is more favorable than ENDRA Life Sciences.

Institutional & Insider Ownership

32.6% of IRIDEX shares are owned by institutional investors. Comparatively, 2.8% of ENDRA Life Sciences shares are owned by institutional investors. 2.0% of IRIDEX shares are owned by insiders. Comparatively, 9.6% of ENDRA Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares IRIDEX and ENDRA Life Sciences' net margins, return on equity and return on assets.

Summary

IRIDEX beats ENDRA Life Sciences on 8 of the 13 factors compared between the two stocks.